Genomic Profiling

We deliver a broad range of sequencing services—tumor tissue and liquid DNA profiling, somatic and germline testing, tumor-normal matched profiling and RNA sequencing—all of which empowers you to make data-driven decisions for your patients.


One partner. Smart Insights.

We offer worldwide access to our comprehensive genomic profiling services and data-driven solutions to help inform patient care and advance precision oncology decisions.
Download our case studies to see how we support sequencing for research, clinical trials, and sponsored testing.

Tempus xT

648 genes by DNA NGS
Whole Transcriptome RNA

Solid Tumor + Normal Test

Tempus xF

xF+: Targeted Panel of 523 genes (available on a limited basis)
xF: Targeted Panel of 105 genes

Liquid Biopsy Test

Tempus xE

19,000+ genes

Whole Exome Test

Download validation summary

Tempus xG (Powered by GeneDx)

88-gene and 52-gene germline panels

xG+ (extended hereditary cancers)
xG (common hereditary cancers)

DNA + RNA Whole Transcriptome Sequencing

29% more patients were identified with a unique clinically actionable fusion matched to a targeted therapy, compared to DNA sequencing alone.1

Solid Tumor and Normal Matched DNA Sequencing

28% reduction in somatic false-positive calls, improving accuracy compared to tumor-only analysis.2

Incidental Germline Findings

7% of patients were found to harbor pathogenic or likely pathogenic germline variants across multiple cancer types and are indicated for confirmatory germline testing, per high risk assessment guidelines.3,4

Concurrent Solid Tumor and Liquid Biopsy Testing

9% of patients had unique actionable variants found in liquid biopsy that were not detected in solid tumor alone.5

Clinical Data Integration

96% of patients matched to a clinical trial when clinical data was combined with Tempus NGS.2

Automatic Conversion Option

In the event of insufficient tumor tissue, convert to liquid biopsy testing for rapid genomic results.

Algorithmic Tests

We provide advanced patient insights without the need for additional tissue.

  1. Based on a retrospective study involving a cohort of randomly selected patients with tumor types including low grade glioma, sarcoma, glioblastoma, bladder, NSCLC and biliary tract cancer. Michuda J, Park BH, Cummings AL, et al. Use of clinical RNA-sequencing in the detection of actionable fusions compared to DNA-sequencing alone. JCO. 2022;40(16_suppl):3077.
  2. Based on a retrospective study involving a cohort of randomly selected patients with tumor types including brain, breast, colorectal, lung, ovarian, endometrial, pancreatic and prostate cancer. Beaubier N, Bontrager M, Huether R, et al. Integrated genomic profiling expands clinical options for patients with cancer. Nat Biotechnol. 2019;37(11):1351-1360.
  3. Based on a retrospective study involving a cohort of randomly selected patients treated in geographically diverse oncology practices in the US with tumor types including bladder, brain, lung, cholangiocarcinoma, head and neck, breast, ovarian, pancreatic, prostate, endometrial and colorectal. Yap TA, Ashok A, Stoll J, et al. Prevalence of germline findings among tumors from cancer types lacking hereditary testing guidelines. JAMA Network Open. 2022;5(5).
  4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic / Familial High- Risk Assessment: Breast, Ovarian, and Pancreatic V.2.2022 © National Comprehensive Cancer Network, Inc. 2022.
  5. Based on a retrospective study involving a cohort of randomly selected patients with breast cancer, CRC, NSCLC, and prostate cancer. Mackay M, Mitsiades N, Chae YK, et al. Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers. JCO. 2022;40(16_suppl):3017.

Clinical support tools & EMR integration

Tempus Hub

Tempus Hub

Our online Hub allows you secure, fast, reliable access to patient report status and results. View interactive and in-depth next-generation sequencing results in the context of a patient’s clinical history, filterable treatment applications and clinical trials, and PDFs of all Tempus reports.

You will also have access to our near real-time support tool that connects you with up-to-date treatment options and relevant insights derived from real-world clinical evidence across millions of de-identified patient records, our vast library of molecular profiling data, and our advanced analytics and machine-learning algorithms.

Download the Tempus mobile app.
The Tempus Order Summary

The Tempus Order Summary

After processing your entire order, we produce an order summary highlighting all key findings from the xT and xF tests along with additional tests like HRD and TO, including actionable treatments, microsatellite instability (MSI) status, and tumor mutational burden (TMB) that can be quickly translated into cancer patient care.

Our reports are also embedded with Tempus Insights, patient-specific insights derived from real-world evidence to empower physicians with the necessary data to improve patient care.

Get in touch to learn more.


Tempus is the first genomic sequencing company to incorporate both Memorial Sloan Kettering Cancer Center’s OncoKB and NCCN Content into smart clinical reports. MSK OncoKB & NCCN are two of the most robust oncology databases in the world. With the integration of these trusted sources, you can:

  • Optimize treatment plans for your patients
  • Stay updated with the latest indications and recommendations
Integration and Connectivity Solutions

Integration and Connectivity Solutions

With a dedicated team of integration experts, we offer a fully interoperable solution for clinical ordering and returning results back into an institution’s health IT systems. We can transform our report into discrete genomic data that can be loaded directly into your system(s) in industry standard HL7 format. In addition, we collaborate with partners to offer a fully interoperable structured result file format which can be parsed and loaded into an institution’s data ecosystem to power their precision medicine program. 

To ease the clinical ordering workflow, we support the automation of appropriate and secure data sharing to power your precision medicine program with Tempus clinical support and advanced analytics. If you have already ordered Tempus through paper or online methods, we can historically backfill prior results into your system(s). 

We understand the power of analytics and the positive impact it has on clinical support.

Contact us today.

The Tempus Sequencing Lab

Bringing data and technology into clinical care

We operate CAP-accredited, CLIA-certified robotic sequencing labs in Chicago, Atlanta, and Raleigh with automated bioinformatics and variant classification reporting. Sequencing is completed within 8–10 days on average of receiving patient samples.

Download our lab overview


The Benefits of Combining Molecular and Clinical Data for Patients

“Extensive molecular profiling combined with clinical data identifies targeted therapies and clinical trials […] and paired tumor/normal plus transcriptome sequencing outperforms tumor-only DNA panel testing.”

Learn more about the xT 500 Publication in Nature Biotechnology

Combined DNA and RNA sequencing using Tempus|xT increased the high level therapy matching rate to 43.4% of patients.

Follow-Up Testing Covered Under Tempus Financial Assistance*

Any US-based patient who receives Tempus testing may apply for our Financial Assistance Program. If approved, the program covers all medically necessary xT (solid), xF (liquid) and xG (hereditary) testing within 18 months of approval.

*Tempus testing is always conducted based on the medical judgment of an ordering physician.

This is data-driven precision medicine.

This is the future of healthcare.